Ensemble is expanding collaboration with Roche

Ensemble Discovery Corp. of Cambridge said today that it has extended its collaboration with drug maker Roche to apply its proprietary diagnostic technology to personalized cancer therapy.

"The collaboration will deploy Ensemble Discovery’s proprietary diagnostic assays (based upon DNA-programmed chemistry) in human clinical studies to analyze combinations of Epidermal Growth Factor Receptors (EGFR) present in cancer tissues," Ensemble Discovery said in a press release.

Ensemble Discovery deploys proprietary chemistry platforms to develop novel classes of therapeutics and diagnostics.

“We are very pleased to extend and expand our collaboration with Roche” Ensemble Discovery chief executive Michael D. Taylor said in a statement. “Roche is one of the world’s leading cancer companies with a strong commitment to personalized healthcare which strives to fit the right treatment to the patient."
(By Chris Reidy, Globe staff)